[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fatigue\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fatigue":33},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,108,0,25,[9,49,83,111,137,166,203,231,258,294,318,343,372,398,427,446,470,497,531,563,584,606,626,649,674],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100645034","effect-of-virtual-reality-guided-imagery-on-pain-anxiety-and-fatigue-in-cancer-patients-undergoing-chemotherapy-100645034",false,"NCT07677436","Effect of Virtual Reality-Guided Imagery on Pain, Anxiety, and Fatigue in Cancer Patients Undergoing Chemotherapy","Effect of Virtual Reality Guided Imagery on Pain, Anxiety, and Fatigue in Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial","VRGI-Chemo Tri","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Histologically confirmed breast cancer.\n* Stage I, II, or III breast cancer.\n* Underwent surgery as the initial treatment and are scheduled to receive the first cycle of adjuvant chemotherapy, with or without biologic therapy (e.g., AC or TC regimens).\n* Able to read, write, and communicate.\n* Able and willing to use a virtual reality headset.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Visual or hearing impairment that prevents the use of virtual reality.\n* Serious neurological or psychiatric disorders.\n* Current participation in other non-pharmacological interventions (e.g., meditation or relaxation therapy) that could influence the study outcomes.\n* Previous experience with virtual reality-guided imagery.\n* Use of analgesics, anxiolytics, or other medications during the intervention that may affect the study outcomes.","FEMALE","18 Years",{"count":5,"type":21},"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled trial aims to evaluate the effectiveness of virtual reality-guided imagery in reducing pain, anxiety, and fatigue among female breast cancer patients undergoing adjuvant chemotherapy. Participants will be randomly assigned to either an intervention group receiving virtual reality-guided imagery in addition to routine care, or a control group receiving routine care",[27,28,29,30,31,32,33],"Virtual Reality","Guided Imagery","Breast Cancer","Chemotherapy","Pain","Anxiety","Fatigue",[35],"Virtual Reality, Guided Imagery , Breast Cancer, Chemotherapy , Pain, Anxiety , Fatigue","NOT_YET_RECRUITING","2026-06-27",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":21},"2026-07-01",{"date":44,"type":21},"2027-03",{"name":46,"class":47},"Thoalfokar Mohammed Al-Obaidi","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100645025","phase-3-a-phase-3-efficacy-and-safety-study-of-hbs-301-in-participants-with-narcolepsy-100645025","NCT07675135","A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy","A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy Followed by an Open-label Extension","Inclusion Criteria:\n\n* Has a current documented diagnosis of NT1 or NT2 per the International Classification of Sleep Disorders, Third Edition (ICSD-3) or the ICSD-3 Text Revision (ICSD-3-TR) within the last 10 years.\n* Has EDS.\n* If taking a permitted chronic concomitant medication or supplement, including nonprohibited antidepressants or wake-promoting agents, must be on a stable dose for at least 3 months prior to Screening and agree to continue at that stable dose for the Double-blind Treatment Period of the study. As needed (PRN) use of any treatment that could affect daytime sleepiness (including but not limited to oxybates, stimulants, modafinil, and armodafinil) is not permitted.\n\nExclusion Criteria:\n\n* Has hypersomnia due to another medical disorder.\n* Has a history of pitolisant use within 5 half-lives prior to Screening.\n* Has a primary diagnosis of psychiatric illness, including depression, that is not well controlled (i.e., symptoms and medications have not been stable for at least 3 months prior to Screening).\n* Has any history of bipolar disorder or psychosis\n* Has acute or chronic liver disease or a history of moderate or severe hepatic impairment.\n* Has a body surface area-corrected estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin.\n* Has a known history of long QT syndrome or serious abnormality of the electrocardiogram (ECG).","ALL",{"count":58,"type":21},258,[60],"PHASE3","This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in treating excessive daytime sleepiness (EDS), cataplexy, sleepiness\u002Fwakefulness, and fatigue in adult participants (ages ≥18 years) with narcolepsy.",[63,64,33,65],"EDS","Cataplexy","Narcolepsy",[67,68,69,63,70,71],"pitolisant","HBS-301","narcolepsy","cataplexy","fatigue","RECRUITING","2026-06-25",{"date":39,"type":40},{"date":76,"type":40},"2026-06-04",{"date":78,"type":21},"2027-11",{"name":80,"class":81},"Harmony Biosciences Management, Inc.","INDUSTRY",14,{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":56,"minAge":19,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":101,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":48},"100638363","photobiomodulation-effects-on-fatigue-and-muscle-damage-induced-by-nmes-100638363","NCT07602933","Photobiomodulation Effects on Fatigue and Muscle Damage Induced by NMES","Effects of Photobiomodulation on Fatigue and Muscle Damage Induced by Neuromuscular Electrical Stimulation in Healthy Individuals: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Healthy male and female volunteers.\n* Age between 18 and 45 years.\n* Practice physical activity regularly\n* No history of musculoskeletal injuries in the lower limbs in the last 6 months\n* Ability to tolerate NMES\n\nExclusion Criteria:\n\n* Have sensory intolerable changes due to NMES\n* Consumed coffee or another stimulant in the last 12 hours\n* Have a body mass index (BMI) greater than 30 kg\u002Fm2 (grade I obesity)\n* Present any contraindication for the performance of maximum effort\n* Abnormal increase in blood pressure after maximal exertion",true,"45 Years",{"count":93,"type":21},36,[24],"Neuromuscular electrical stimulation (NMES) is widely used to improve muscle strength and mitigate atrophy. However, its clinical efficacy is often limited by early neuromuscular fatigue, muscle damage, and discomfort, which reduce patient tolerance and contraction time. Photobiomodulation (PBM) has emerged as a potential therapy to enhance muscle performance and accelerate recovery by minimizing fatigue and damage. Despite its potential, few studies have investigated the effects of PBM applied specifically before an NMES-evoked fatigue protocol. This randomized, double-blind, placebo-controlled trial aims to evaluate the acute effects of PBM on neuromuscular fatigue, muscle damage, and functional outcomes in healthy young subjects. Participants will receive either active PBM (cluster probe: 5 lasers 810nm\u002F200mW; 4 LEDs 660nm\u002F10mW; Total Energy: 249.6 J per limb) or sham treatment 5 minutes before a fatiguing NMES protocol (80 contractions at 20% MVIC, 80 Hz, 1ms pulse width) applied to the quadriceps muscle. Assessments will be performed at baseline, immediately post-intervention, and at 24h, 48h, and 72h post-intervention. Primary outcomes include maximum and evoked isometric strength, mechanical work, and electrical muscle activity. Secondary outcomes include muscle damage (ultrasound echo-intensity), delayed onset muscle soreness (DOMS), functional performance (unilateral vertical jump), and clinical discomfort. The study seeks to determine if PBM can effectively modulate NMES-induced fatigue and muscle damage, potentially optimizing its clinical application.",[97,33,98,99,100],"Photobiomodulation","Discomfort","Electrical Stimulation","Muscle Damage",[97,33,98,100,102],"Electrical stimulation","2026-06-24",{"date":73,"type":40},{"date":106,"type":21},"2026-06-01",{"date":108,"type":21},"2026-09-30",{"name":110,"class":47},"Federal University of Rio Grande do Sul",{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":48},"100490275","the-safety-and-efficacy-of-redsenol-1-plus-on-cancer-related-fatigue-in-adults-100490275","NCT05664009","The Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults","A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults","Inclusion Criteria:\n\n1. Males and females ≥18 years of age\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,\n\n   Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n3. Individuals previously diagnosed with cancer and have CRF defined as a score of ≥4 on the CRF Single-Item Scale (an 11-point scale where 0 is \"no fatigue\" and 10 is \"as bad as it can be\")\n4. CRF present for at least one month prior to screening\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score ≤2\n6. Hemoglobin level of ≥110 g\u002FL for females and ≥129 g\u002FL for males at screening\n7. Agrees to maintain current lifestyle habits as much as possible throughout the study depending on ability to maintain the following: diet, medications, supplements, exercise, and sleep and avoid taking new supplements during the study period\n8. Provided voluntary, written, informed consent to participate in the study\n9. Otherwise healthy as determined by medical history and laboratory results as assessed by Qualified Investigator (QI) while taking into consideration the participant's cancer history\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance to the investigational product's or placebo's active or inactive ingredients\n3. Individuals with any CNS malignancies (e.g., brain or spine) and\u002For estrogen-receptor positive breast cancer\n4. Individuals with other primary causes of fatigue, as assessed by the QI (e.g., diagnosed non-cancer related chronic pain, insomnia\u002Fsleep disorders, depression\u002Fpsychiatric disorders, unstable hypothyroidism, diabetes, gastrointestinal disease or symptoms that can affect nutritional balance)\n5. Individuals with unstable medical conditions as assessed by the QI\n6. Individuals with current untreated\u002Funcontrolled high blood pressure or tachycardia\u002Fheart rhythm disorders\n7. Individuals with \\>7.5% HbA1c with treatment for high blood sugar\u002Fdiabetes or individuals with ≥6.5% HbA1c without treatment\n8. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n9. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n10. Major non-cancer surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n11. Current use of prescription\u002FOTC medications and\u002For supplements and food\u002Fdrinks which may affect the efficacy and\u002F or safety of the IP (see Sections 5.4.1 and 5.4.2)\n12. Alcohol or drug abuse within the last 12 months\n13. Frequent (daily) and chronic cannabis users. Occasional (e.g., once per month) cannabis users may be included at the discretion of the QI and if eligible, asked to stop cannabis use for study period\n14. Clinically significant abnormal laboratory results inclusive of thyroid stimulating hormone at screening as assessed by the QI\n15. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n16. Individuals who are unable to give informed consent\n17. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",{"count":119,"type":21},72,[24],"The primary objective of this study is to evaluate the safety and efficacy of Redsenol-1 Plus on cancer-related fatigue (CRF) in adults. The change in the severity of CRF from baseline at week 12 will be assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) fatigue subscale, and compared between Redsenol-1 Plus and placebo groups. Additionally, the safety and tolerability of Redsenol-1 Plus, as compared to placebo, will be measured by the occurrence of and\u002For changes in treatment-emergent adverse events (AEs).",[33,123],"Cancer, Treatment-Related",[125,126,127],"Safety and efficacy","Cancer-related fatigue","Ginseng","2026-06-23",{"date":130,"type":40},"2026-06-26",{"date":132,"type":21},"2026-08",{"date":134,"type":21},"2026-12",{"name":136,"class":81},"Canada Royal Enoch Phytomedicine Co., Ltd.",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100643932","phase-3-evaluation-of-nuvastatictm-in-reducing-cancer-related-fatigue-in-stage-iv-colon-cancer-patients-undergoing-first-line-chemotherapy-100643932","NCT07669519","Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line Chemotherapy","Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line Chemotherapy","NuvastaticTM","Inclusion Criteria:\n\n1. Male and female Patients who are ≥18 and ≤65 years of age, who are willing to voluntarily provide consent for participation in the study.\n2. Patients with colon cancer planned or scheduled to receive standard chemotherapy treatment for at least 3 cycles respectively.\n3. Patients must have a confirmed diagnosis of colon cancer as per standard guideline.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening.\n5. The patient has stable haemoglobin (≥ 9 g\u002FdL) throughout the screening.\n6. Life expectancy ≥ 6 months, as per Investigator's judgment\n7. Patients with co-morbidities or medical conditions including Type 2 DM, hypertension and are deemed stable by the investigator can be included in the study\n8. At screening patients with stable fatigue, has a newly developed fatigue OR worsening of fatigue scoring as assessed by BFI should be included.\n9. Starting first-line chemo\n\nExclusion Criteria:\n\n1. Patients who have any untreated reversible medical condition which may cause fatigue (e.g. metabolic disturbance, infection, endocrine abnormalities) as per the Investigator's clinical judgment.\n2. Patients who have stage IV Disease\n3. Patients who have received concurrent stimulant medication (e.g. dextroamphetamine or methylphenidate) during the screening period or any medication which may interfere with study drug.\n4. Prior metastatic chemo, targeted\u002Fimmunotherapy, severe comorbidities\n5. Female patients who are pregnant or breast-feeding.\n6. Patients with known hepatitis C virus, hepatitis B virus, HIV infection.\n7. Patients who have nausea and vomiting or any gastrointestinal disorder that is severe enough to interfere with study drug absorption in the opinion of the Investigator.\n8. Patients with uncontrolled pain, who in the opinion of the Investigator are not eligible for the study. '\n9. Patients with planned therapy or treatment with another investigational agent.\n10. Previous exposure to any investigational agent within 4 weeks prior to screening, or planned administration of an Investigational agent, other than as specified by this protocol, during the study period.","65 Years",{"count":147,"type":21},180,[60],"The goal of this clinical trial is to evaluate whether Nuvastatic can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy.\n\nThe main questions it aims to answer are:\n\nDoes Nuvastatic significantly reduce cancer-related fatigue compared to placebo? Is Nuvastatic safe and well tolerated in this patient population?\n\nResearchers will compare Nuvastatic vs placebo to see if Nuvastatic improves fatigue scores and maintains an acceptable safety profile.\n\nParticipants will:\n\nReceive Nuvastatic or placebo sachets (3 times per day) for 3 cycles of 20 days each (total \\~60 treatment days).\n\nContinue their standard first-line chemotherapy regimen. Provide blood samples for biomarkers (CEA, CA-125) at Screening and End of Treatment.\n\nComplete patient diaries and fatigue assessments as per protocol.",[33,151],"Colon Cancer",[151,153,154,155,156],"Cancer-Related Fatigue","Nuvastatic","Randomized Double-Blind Placebo-Controlled Trial","First-Line Chemotherapy","2026-06-22",{"date":73,"type":40},{"date":160,"type":40},"2025-08-18",{"date":162,"type":21},"2027-03-31",{"name":164,"class":81},"Natureceuticals Sdn Bhd",6,{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":177,"conditions":178,"keywords":188,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100637471","balance-gait-and-motion-analysis-in-multiple-sclerosis-100637471","NCT07630311","\"Balance, Gait, and Motion Analysis in Multiple Sclerosis\"","\"Functional Assessment of Balance and Gait and Correlation With Kinetic and Kinematic Parameters in Patients With Multiple Sclerosis: Cross-Sectional Study\"","MS-BALGAIT","Inclusion Criteria:\n\n* Adults (≥ 18 years) with confirmed diagnosis of Multiple Sclerosis\n* Expanded Disability Status Scale (EDSS) score \\\u003C6\n* Ability to ambulate independently without the use of assistive devices\n* Absence of significant orthopedic or neurological conditions affecting mobility\n* Ability to understand and follow verbal instructions.\n\nExclusion Criteria:\n\n* History of injury or surgical intervention to the lower limbs or spine within the past year\n* Any musculoskeletal, neurological, cardiovascular, or other medical condition, other than Multiple Sclerosis, that may significantly affect gait or balance or compromise participant safety during testing.\n* Severe balance impairment or high risk of falling that prevents safe participation in single-leg stance, gait analysis, or obstacle negotiation tasks.",{"count":175,"type":21},40,"OBSERVATIONAL","The goal of this observational cross-sectional study is to investigate the relationship between functional measures of balance and gait and objective kinetic and kinematic parameters in people with Multiple Sclerosis (MS).\n\nThe main questions it aims to answer are:\n\ni) What is the relationship between kinetic and kinematic gait and balance parameters measured using the Vicon motion analysis system and performance on clinical functional assessments in people with Multiple Sclerosis?\n\nii) Which biomechanical parameters are most strongly associated with functional balance, gait, and physical performance outcomes?\n\nParticipants will attend a single laboratory-based assessment session. During this session, they will undergo biomechanical gait and balance analysis using the Vicon motion capture system, complete functional assessments of balance, gait, and physical performance, complete questionnaires assessing fear of falling and fatigue, and undergo assessment of lower-limb spasticity.",[179,180,181,182,183,184,185,186,33,187],"Multiple Sclerosis","Gait Disorders, Neurologic","Postural Balance","Motion Analysis","Biomechanics","Kinetics","Kinematics","Physiotherapy","Fall",[179,189,190,182,191,192,193,33,183],"Balance","Gait","Vicon System","Functional Assessments","Physical Performance","2026-06-21",{"date":103,"type":40},{"date":197,"type":40},"2025-09-01",{"date":199,"type":21},"2026-08-30",{"name":201,"class":47},"University of Patras",2,{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":90,"sex":56,"minAge":145,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":213,"conditions":214,"keywords":219,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":48},"100643936","cognitive-reserve-and-post-fatigue-recovery-in-older-adults-100643936","NCT07667985","Cognitive Reserve and Post-Fatigue Recovery in Older Adults","Determining the Post-Physical and Mental Fatigue Recovery Perspectives of Older Adults Based on Their Cognitive Reserves","Inclusion Criteria:\n\n* being 65 years of age or older,\n* not having any neurological, psychiatric, or systemic disease that would affect one's mental state, and not using any medication for these conditions.\n\nExclusion Criteria:\n\n* Being younger than 65 years old,\n* having an illness or taking medication that affects mental health, or being\n* unable to complete the questionnaires.","90 Years",{"count":212,"type":21},400,"As people grow older, it is common to experience a drop in physical stamina and memory functions. This can make recovering from daily physical and mental fatigue more difficult, which directly impacts an individual's independent daily life and overall quality of life.\n\n\"Cognitive reserve\" is a term that describes the brain's built-in resilience. Built over a lifetime through education, work, and social activities, a higher cognitive reserve acts like a buffer, helping the brain adapt to stress and aging. While research shows that a high cognitive reserve protects against conditions like dementia, we still do not fully understand how it helps older adults bounce back from normal, everyday physical and mental exhaustion.\n\nThe goal of this study is to investigate how cognitive reserve levels influence how individuals aged 65 and older perceive their recovery after experiencing physical and mental fatigue.\n\nWhat the Study Involves\n\nThe researchers will evaluate participants aged 65 and older to measure their baseline cognitive reserve levels. The study will look closely at how these levels affect the participants':\n\nAbility to cope with daily physical and mental fatigue. Need for rest and rest patterns. Time and ability to return to normal daily activities. Overall perception of their mental and physical recovery. Expected Outcome By understanding this relationship, the study aims to fill a gap in medical literature and help healthcare providers design better, more personalized rehabilitation and lifestyle support programs to improve the quality of life for older adults.",[215,216,217,33,218],"Cognitive Reserve","Aging","Mental Fatigue","Recovery of Function",[220,221,71,222],"aging","cognitive reserve","Post-Fatigue Recovery","2026-06-19",{"date":73,"type":40},{"date":226,"type":40},"2026-06-20",{"date":228,"type":21},"2026-09-22",{"name":230,"class":47},"Uşak University",{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":56,"minAge":239,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":48},"100514337","dietary-intervention-to-mitigate-post-acute-covid-19-syndrome-100514337","NCT05977179","Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome","A Diet Intervention Study To Mitigate Fatigue Symptoms And To Improve Muscle And Physical Function In Older Adults With Post-Acute COVID-19 Syndrome","Long-COVIDiet","Inclusion Criteria:\n\n1. Age of 50 years or older\n2. No known active infectious disease (COVID-19 or other).\n3. Participant diagnosed with long-COVID\u002F post- acute COVID-19 syndrome (PACS) \u002FICD-10-CM codes U09.9\n4. Moderate\u002Fsevere fatigue Brief Fatigue Inventory (BFI)≥4\n5. Poor diet quality assessed by the short Healthy Eating Index (HEI)\\\u003C70\n\nExclusion Criteria:\n\n1. Participants with a home oxygen requirement or requiring chronic ventilator support\n2. Participants diagnosed with diabetes who do not have a recent HbA1c level or with HbA1c \\> 9%\n3. Participants diagnosed with Congestive Heart Failure (CHF New York Heart Association) \\> class 2\n4. Participants with dietary restrictions due to medication use that affects blood clotting, such as Warfarin or other reasons.\n5. Evidence of any condition as determined by a physician or the study team that would lead to an increased risk of illness due to any aspect of proposed testing and interventions, or introduce unanticipated confounding of study results.\n6. Participants diagnosed with uncontrolled hypertension that will be defined as:\n\n   1. Systolic blood pressure consistently equal to or higher than 190 mmHg.\n   2. Diastolic blood pressure consistently equal to or higher than 110 mmHg.\n   3. Participants with a recent history of hypertensive crisis (severe elevation in blood pressure requiring immediate medical intervention), regardless of current blood pressure levels.\n7. Participants with diet restrictions or allergies that can affect adherence to the diet, such as allergy to fish or shellfish.\n8. Participation in another trial in which active intervention is being received.\n9. Participants with active drug or alcohol use\u002Fdependence that would interfere with adherence to the study.\n10. Participants scheduled for surgical procedures within the next 6 months.\n11. Participants diagnosed with active cancer.\n12. Participants diagnosed with liver diseases.\n13. Participants diagnosed with kidney-related conditions, including Chronic Kidney Disease (CKD) \\> stage 3.\n14. Below the age of 50 years.","50 Years","94 Years",{"count":242,"type":21},56,[24],"The primary objective of this study is to conduct a 16-week randomized controlled trial aimed at investigating the effectiveness of the Whole-Diet Approach when following a healthy US-style diet rich in anti-inflammatory properties. The study will focus on evaluating its impact on reducing symptoms related to Post-Acute Sequelae of SARS-CoV-2 Infection (PACS) in adults aged 50 years and older.\n\nThe main research questions this study aims to answer are:\n\n1. Does adhering to a healthy US-style diet, which is abundant in anti-inflammatory properties, effectively mitigate fatigue symptoms in adults with PACS?\n2. Does adhering to a healthy US-style diet, which is abundant in anti-inflammatory properties, effectively mitigate declines in muscle function and physical performance in adults with PACS?\n\nAt the beginning of the study, eligible participants will be randomly assigned to either the Dietary Intervention Group, where they will receive personalized dietary plans and weekly sessions, or the Attention Control Group, where they will attend general health sessions on a weekly basis as well.\n\nThis research intends to shed light on the potential benefits of the Whole-Diet Approach and its role in ameliorating PACS-related symptoms among older adults. By comparing the outcomes of the two groups, we hope to gain valuable insights into the effectiveness of this dietary intervention in improving the quality of life for individuals dealing with PACS.",[246,33],"Post-Acute COVID-19 Syndrome",[248,249,250],"COVID","long-COVID","DIET",{"date":128,"type":40},{"date":253,"type":40},"2025-05-12",{"date":255,"type":21},"2028-09-30",{"name":257,"class":47},"University of Maryland, Baltimore",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":90,"sex":56,"minAge":265,"maxAge":145,"enrollmentInfo":266,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":268,"conditions":269,"keywords":275,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":48},"100644217","non-invasive-sleep-monitoring-for-burnout-and-retention-risk-in-postgraduate-nurses-100644217","NCT07666633","Non-Invasive Sleep Monitoring for Burnout and Retention Risk in Postgraduate Nurses","Development of a Non-Invasive Sleep-Based Prediction Platform for Burnout and Retention Risk Among Postgraduate Nurses: A Psychophysiological and AI-Driven Approach for High-Stress Clinical Populations","Inclusion Criteria:\n\n* Newly employed postgraduate nurses within the first 3 months of clinical practice\n* Age 20 to 65 years\n* Full-time clinical nursing staff\n* Able to read and complete Chinese questionnaires\n* Willing to participate in repeated psychological assessments and non-invasive sleep monitoring\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Diagnosed severe sleep disorders\n* Diagnosed severe psychiatric disorders\n* Current use of medications that significantly affect sleep or autonomic nervous system function\n* Inability to comply with longitudinal follow-up procedures\n* Inability to complete repeated sleep monitoring assessments","20 Years",{"count":267,"type":21},100,"Newly graduated nurses often experience high levels of psychological stress, sleep disturbance, fatigue, and burnout during the early transition into clinical practice. Early identification of burnout and retention risk may help improve mental well-being, workforce stability, and quality of patient care.\n\nThis longitudinal observational study aims to develop a non-invasive sleep-based prediction platform for assessing burnout and retention risk among postgraduate nurses. Participants will undergo repeated psychological assessments and non-contact sleep monitoring during the study period. Sleep-related physiological parameters, including sleep efficiency, sleep structure, heart rate variability, and respiratory variability, will be collected together with validated psychological questionnaires.\n\nThe study will further apply machine learning and artificial intelligence approaches to integrate longitudinal physiological and psychological data for risk prediction and early identification of burnout-related conditions. The findings may support future development of precision mental health monitoring and supportive management strategies for high-stress healthcare workers.",[270,271,272,273,274,33],"Burnout","Sleep Disturbance","Occupational Stress","Mental Health","Nurse Retention",[276,277,278,279,280,281,282,283,284,285],"Postgraduate Nurses","Non-Invasive Sleep Monitoring","Burnout Risk","Retention Risk","Artificial Intelligence","Machine Learning","Sleep Quality","Heart Rate Variability","Shift Work","Psychological Stress","2026-06-18",{"date":103,"type":40},{"date":289,"type":21},"2026-08-01",{"date":291,"type":21},"2027-04-23",{"name":293,"class":47},"Kaohsiung Armed Forces General Hospital",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":90,"sex":56,"minAge":301,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":314,"leadSponsor":316,"locationsCount":48},"100641383","radicle-energy-vbmtm-a-study-assessing-the-impact-of-health-and-wellness-products-on-fatigue-and-related-health-outcomes-100641383","NCT07653724","Radicle Energy VBMTM: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes","Radicle Energy VBMTM: A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes","Participants must meet all the following criteria:\n\n* Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n\n  * Assigned sex at birth will determine sex-specific recruitment and PROs (male vs female) employed, when needed\n* Resides in the United States\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study\n\n3.2 Exclusion\n\nIndividuals who report any of the following during screening may be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English at a 7th grade level\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n\n  * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.\n\n  * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products\n* Reports current use of caffeine-alternative products\n* Reports consuming 3 or more caffeinated beverages a day\n* Lack of reliable daily access to the internet","21 Years","105 Years",{"count":304,"type":21},550,[24],"Radicle Energy VBMTM: A randomized, double-blind, placebo- controlled direct-to-consumer study assessing the impact of health and wellness products on fatigue and related health outcomes.",[33,308,309,271],"Cognitive Function","Global Mental Health","2026-06-12",{"date":312,"type":40},"2026-06-17",{"date":73,"type":21},{"date":315,"type":21},"2027-06-25",{"name":317,"class":81},"Radicle Science",{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":56,"minAge":326,"maxAge":19,"enrollmentInfo":327,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":329,"conditions":330,"keywords":334,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":48},"100642191","core-stability-functional-capacity-balance-strength-and-fatigue-in-pediatric-demyelinating-diseases-100642191","NCT07654738","Core Stability, Functional Capacity, Balance, Strength, and Fatigue in Pediatric Demyelinating Diseases","Investigation of the Relationship Between Core Stability, Functional Capacity, Balance, Lower Extremity Strength, and Fatigue in Pediatric Demyelinating Diseases","PEDI-CORE","Inclusion Criteria:\n\n* Age between 6 and 18 years\n* Diagnosed with a pediatric demyelinating disease\n* No relapse within the last 3 months\n* No botulinum toxin (Botox) injections within the last 3 months\n* No corticosteroid treatment within the last 3 months\n* Ability to read and write\n\nExclusion Criteria:\n\n* History of concomitant autoimmune diseases\n* Refusal of the patient and\u002For caregiver to participate in the study\n* History of another primary neurological disease\n* Cognitive impairment that limits understanding of instructions and participation in assessments\n* Visual and\u002For hearing impairments that interfere with activities of daily living\n* Presence of additional rheumatological conditions that may interfere with assessments\n* Spasticity grade ≥2 according to the Modified Ashworth Scale in any muscle group","6 Years",{"count":328,"type":21},32,"This study aims to evaluate balance ability, core stability, functional capacity, lower extremity muscle strength, and fatigue levels in children diagnosed with central nervous system demyelinating diseases, in order to contribute to the development of evidence-based and individualized rehabilitation strategies.",[331,332,333,189,33],"Demyelinating Diseases of the Central Nervous System","Child","Core Stability",[335,333,189,33],"Pediatric Demyelinating Diseases",{"date":312,"type":40},{"date":338,"type":21},"2026-07-30",{"date":340,"type":21},"2028-01-30",{"name":342,"class":47},"Istanbul University - Cerrahpasa",{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":22,"phases":351,"briefSummary":352,"conditions":353,"keywords":357,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":48},"100491071","training-in-evidence-based-treatments-in-psycho-oncology-100491071","NCT05674357","Training in Evidence-based Treatments in Psycho-Oncology","Patient Inclusion Criteria:\n\n* Adults \\> 18 years of age.\n* Currently receiving oncology treatment\u002Fcare at the MGH Cancer Center, including active treatment and\u002For surveillance.\n* Reports elevated levels of distress on the National Comprehensive Cancer Network (NCCN) Distress Thermometer \\> 3.\n* Reports distress or presenting problem is related to patients' illness and\u002For treatment (e.g., cancer treatment).\n* Has a clinical presentation that matches an evidence-based treatment (e.g., CBT-I for insomnia\u002Fsleep disturbance) for cancer-related distress per therapist and supervising therapist discretion.\n* Located in the state of Massachusetts for the duration of sessions.\n\nCaregiver Inclusion criteria:\n\n* Adults \\> 18 years of age\n* Currently caring for someone receiving oncology treatment\u002Fcare at the MGH Cancer Center, including active treatment and\u002For surveillance\n* Reports elevated levels of distress on the National Comprehensive Cancer Network (NCCN) Distress Thermometer \\> 3\n* Reports distress or presenting problem is related to caregiving\n* Has a clinical presentation that matches an evidence-based treatment (e.g., CBT-I for insomnia\u002Fsleep disturbance) for caregiving-related distress per therapist and supervising therapist discretion\n* Located in the state of Massachusetts for the duration of sessions\n\nPatient Exclusion Criteria:\n\n* Has uncontrolled psychosis, active suicidal ideation, or psychiatric hospitalization within the past year (assessed through EHR review and screening session using the QuickSCID-5), indicating the need for tailored treatment referral to specialty mental healthcare outside of psycho-oncology or to a higher level of care such as an intensive outpatient program (IOP).\n* Has a cognitive impairment that prohibits participation in the study (assessed through EHR review and screening session).\n* Currently participating in group or individual evidence-based psychotherapy treatment or other psychosocial intervention trial.\n* Has an alcohol or substance dependence (other than nicotine dependence) in the past 8 weeks (assessed through EHR review and screening session using the QuickSCID-5), indicating the need for tailored treatment referral to specialty mental healthcare outside of psycho-oncology or to a higher level of care such as an intensive outpatient program (IOP).\n\nTherapist Inclusion criteria:\n\n-Current appointment as a clinical psychology fellow or psychiatry resident at the Massachusetts General Hospital or equivalent designation.\n\nTherapist Exclusion criteria:\n\n-Obtained licensure as a clinical psychologist in any state.",{"count":350,"type":21},115,[24],"The goal of this research study is to train psychotherapists to administer individualized evidence-based psychotherapies in a cancer care setting to patients and caregivers with elevated levels of distress.\n\nThe intervention will mirror clinical care in psycho-oncology in which the therapist, collaboratively with their supervisor, will choose specific components of the following evidence-based treatments to administer based on the clinical presentation of the patient or caregiver and referring problem.\n\n* Cognitive Behavioral Therapy (CBT)\n* Acceptance Commitment Therapy (ACT)\n* Mindfulness-Based Cognitive Therapy (MBCT)\n* Mindfulness-Based Stress Reduction (MBSR)\n* Meaning-Centered Psychotherapy (MCP)\n* Cognitive Behavioral Therapy for Insomnia (CBT-I)\n* CBT for other cancer-related physical symptoms like pain, fatigue, and nausea.\n\nParticipation in this research study is expected to last about 26 weeks.\n\nIt is expected that about 75 patients, 25 caregivers, and 15 therapists will take part in this research study.",[354,355,33,31,356],"Distress, Emotional","Depression, Anxiety","Insomnia",[358,359,360,32,361,362],"CBT","Cognitive-Behavioral Therapies","Emotional Distress","Depression","Symptom-Related Distress","2026-06-11",{"date":365,"type":40},"2026-06-15",{"date":367,"type":40},"2023-01-09",{"date":369,"type":21},"2029-01-01",{"name":371,"class":47},"Massachusetts General Hospital",{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":22,"phases":381,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":48},"100553163","phase-2-take-the-reins-the-effects-of-nutrient-timing-on-cancer-related-fatigue-100553163","NCT06482515","Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue","Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue Among Blood Cancer Survivors (2458GCCC)","Inclusion criteria (Participants must…):\n\n* Have a diagnosis of a hematologic neoplasm (e.g., leukemia, lymphoma, multiple myeloma);\n* Be at least 2 months post-treatment with chemotherapy, radiation, targeted therapy, chimeric antigen receptor (CAR)-T cell therapy, stem cell transplant, or another therapy (maintenance therapies are okay; steady unchanged treatment for relapsed disease for \\>2 months and expected to stay on it until progression is okay);\n* Have a baseline level of fatigue, as determined by at least one of the following:\n\n  1. Reporting a score of 4 or higher in response to the question, \"What was your worst fatigue in the last week, on a scale of 0-10, where 0 is no fatigue and 10 is the worst fatigue?\"\n  2. In the habit of taking daytime naps,\n  3. Have fatigue that interferes with their ability to work, engage in social events, or is more than would be expected from physical exertion,\n* Be able to speak and\u002For read and write in English or Spanish;\n* Be at least 18 years old; and\n* Be able to provide informed consent.\n\nExclusion criteria (participants must not…)\n\n* Be underweight, as defined as a body mass index \\\u003C18.5 kg\u002Fm2;\n* Already eat all their food within a window that is 10 h or shorter most (6\u002F7) days of the week;\n* Be employed in a job where they regularly work away from the home at night (e.g., night shift);\n* Have surgery planned during the study duration;\n* Have any contraindications to the proposed nutrition intervention as identified by their medical provider, their designee, or the study team (e.g., type 1 diabetes, risk for hypoglycemia, medication requirements, pregnancy, breastfeeding, recent history of an eating disorder);\n* Be taking insulin; or\n* Be on enteral or parenteral nutrition.",{"count":380,"type":21},96,[382],"PHASE2","Cancer-related fatigue affects at least 30-90% of patients with cancer, depending on the type of cancer and their treatment(s) (e.g., chemotherapy, radiation). It is not relieved by sleep or rest, and it sometimes can persist for years after a person's cancer was treated. The fatigue can be so bad that people cannot return to work, hobbies, family roles, or other daily activities, thereby greatly reducing quality of life. The causes of this fatigue are unknown, and we currently do not have anything that can reliably prevent or cure the fatigue. However, there are recent data suggesting that circadian rhythm, or a person's internal body clock, may be disrupted by the cancer experience and contribute to fatigue. Food intake is an external cue that can entrain circadian rhythm. We recently showed that cancer survivors are willing and able to eat all their food within a 10-hour eating window-a practice called time-restricted eating. Herein, we are testing time-restricted eating against a control group (matched for time-, attention, and expectancy) to see if time-restricted eating can indeed alleviate cancer-related fatigue. All participants will be asked to use the myCircadianClock smartphone app to log their food intake and weekly body weight measurements. The participants assigned to the time-restricted eating group will be asked to eat all their food in a 10-hour window during the day. People can choose their start time based on their schedule and preferences, but we ask that the window is the same for the whole study (e.g., 7am-5pm,9:30am-7:30pm). Black coffee and unsweetened tea are allowed before the eating window, and water and medicines are allowed at all times. The participants in the control group will meet with a nutritionist to discuss the American Cancer Society nutrition guidelines in cancer survivorship; they will not be restricted to when they can eat. Participants in both groups will give us valuable information regarding how diet is related to the experience of fatigue. The purpose of this study is to test the effects of a 12-week TRE intervention vs. an unrestricted eating pattern on fatigue, the sustainability of the program at 24 weeks, and the effects of TRE on circadian rhythm and sugar metabolism.",[385,386,33,387,388,389],"Neoplasms","Blood Cancer","Diet Habit","Survivorship","Fasting, Intermittent","2026-06-03",{"date":392,"type":40},"2026-06-05",{"date":394,"type":40},"2024-11-04",{"date":396,"type":21},"2028-08-31",{"name":257,"class":47},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":406,"briefSummary":407,"conditions":408,"keywords":413,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":426},"100637389","the-effect-of-progressive-muscle-relaxation-and-deep-breathing-exercises-applied-to-palliative-care-cancer-patients-on-dyspnea-fatigue-and-self-care-behaviors-100637389","NCT07619209","The Effect of Progressive Muscle Relaxation and Deep Breathing Exercises Applied to Palliative Care Cancer Patients on Dyspnea, Fatigue, and Self-Care Behaviors","Inclusion Criteria:\n\n* Being 18 years of age or older\n\nBeing literate (able to read and write)\n\nHaving no significant hearing or visual impairment that prevents communication or cooperation\n\nReceiving treatment in the palliative care unit\n\nHaving a confirmed medical diagnosis of cancer\n\nHaving a Glasgow Coma Scale (GCS) score of 10 or higher\n\nBeing able to communicate via telephone and SMS for post-discharge follow-up\n\nHaving a Common Terminology Criteria for Adverse Events (CTCAE) Dyspnea Classification of Grade 3 or below\n\nHaving an ECOG Performance Status Scale score of 3 or below\n\nHaving a Hemoglobin (Hb) value of 8 gm\u002FdL or higher\n\nVolunteering to participate in the study and providing informed consent\n\nExclusion Criteria:\n\n* Currently practicing or having recently practiced Progressive Muscle Relaxation (PMR) or deep breathing exercises actively\n\nHaving a primary respiratory system disease diagnosis (such as COPD, asthma, or pneumonia)\n\nHaving a medical diagnosis of dementia, agitation, or delirium\n\nReceiving Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPAP) support\n\nBeing on active antipsychotic or sedative medical treatment\n\nHaving a Common Terminology Criteria for Adverse Events (CTCAE) Dyspnea Classification of Grade 4 or higher",{"count":405,"type":21},90,[24],"The purpose of this study is to evaluate the effects of Progressive Muscle Relaxation (PMR) exercises and deep breathing exercises on dyspnea, fatigue, and self-care behaviors among cancer patients receiving palliative care. Advanced-stage cancer patients frequently experience debilitating symptoms such as shortness of breath (dyspnea) and severe fatigue, which significantly impair their functional capacity and daily self-care activities. Participants in this study will be assigned to either a progressive muscle relaxation intervention group or a structured deep breathing exercise group. The study aims to determine whether these non-pharmacological relaxation techniques can effectively reduce the severity of dyspnea and fatigue, thereby improving the patients' overall self-care behaviors and physical comfort in a palliative care setting.",[409,33,410,411,412],"Cancer","Palliative Care","Progressive Muscle Relaxation","Patient",[410,414,411,415,416,153,417,418],"Cancer Patients","Deep Breathing Exercises","Dyspnea Management","Self-Care Behaviors","Randomized Controlled Trial","2026-05-30",{"date":390,"type":40},{"date":422,"type":40},"2026-01-01",{"date":134,"type":21},{"name":425,"class":47},"Ankara University",4,{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":22,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":48},"100585848","active-living-after-cancer-implementation-within-be-well-acres-homes-100585848","NCT06907706","Active Living After Cancer: Implementation Within Be Well Acres Homes","Inclusion Criteria:\n\n1. Past diagnosis of invasive cancer, or a caregiver (family or friend) of a participating survivor.\n2. No longer receiving treatment for cancer (except hormone therapy or long-term maintenance chemotherapy).\n3. Over the age of 18.\n4. Screen negative for contraindicating health problems on the adapted Physical Activity Readiness Questionnaire (PAR-Q),79 or screened positive but have approval from a health care provider to participate.\n5. Lives in the Acres Homes neighborhood of Houston, Texas or has a home zip code of 77088 or 77091.\n6. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. Women who are pregnant (as indicated by self-report).\n2. Has participated in the ALAC program within the past year and attended more than 2 group sessions.",{"count":434,"type":21},164,[24],"The goal of this research study is to learn more about a physical activity program adapted for cancer survivors.",[409,33],"2026-05-28",{"date":106,"type":40},{"date":441,"type":40},"2023-04-03",{"date":443,"type":21},"2029-04-30",{"name":445,"class":47},"M.D. Anderson Cancer Center",{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":301,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":22,"phases":454,"briefSummary":455,"conditions":456,"keywords":458,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":426},"100601873","exercise-therapy-and-cognitive-behavioural-therapy-for-fatigue-in-female-cancer-patients-in-singapore-100601873","NCT07116161","Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore","Pilot Study of Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore","Inclusion Criteria:\n\nPrimary cohort (N=90):\n\n1. Female\n2. ≥21 years of age\n3. Stage I-III breast cancer regardless of hormone receptor status or human epidermal growth factor receptor 2 (HER2) status\n4. Completed surgery\n5. Completed adjuvant chemotherapy, if indicated\n6. Reported fatigue (One-item fatigue scale score ≥ 4)\n7. Ability to read and communicate in English\n8. Willing to provide informed consent for the study participation\n\nExploratory cohort (N=10):\n\n1. Female\n2. ≥21 years of age\n3. Stage IV breast cancer regardless of hormone receptor status or human epidermal growth factor receptor 2 (HER2) status\n4. Completed surgery\n5. Currently receiving systemic therapy (e.g. endocrine therapy, chemotherapy, targeted therapy or immunotherapy)\n6. Reported fatigue (One-item fatigue scale score ≥ 4)\n7. Ability to read and communicate in English\n8. Willing to provide informed consent for the study participation\n\nExclusion Criteria for both cohorts:\n\n1. Pregnant or lactating\n2. Presence of dementia or major psychiatric disease\n3. Deemed medically unsuitable by medical team for low to moderate intensity exercise\n4. Unable or unwilling for tele-counselling sessions\n5. Uncontrolled pain or undiagnosed pain\n6. Low blood counts: Hb \\\u003C8.0, Platelet \\\u003C50K, ANC \\\u003C1\n7. Electrolyte imbalances: K \\\u003C3.0, Na \\\u003C130\n8. Cardiovascular diseases, including but not limited to: LVEF \\\u003C35%, uncontrolled arrhythmias, severe coronary artery disease, severe valvular heart disease, uncontrolled hypertension etc. not cleared by a cardiologist\n9. Active infection\n10. Currently engaged in moderate to vigorous physical activity",{"count":267,"type":21},[24],"The purpose of this research study is to investigate the acceptability, feasibility, and effectiveness of exercise therapy and cognitive behavioral therapy (CBT) in improving fatigue levels and breast cancer treatment adherence in breast cancer patients.",[33,457],"Breast Cancer Female",[459,460],"Exercise Therapy","Cognitive Behavioural Therapy","2026-05-27",{"date":463,"type":40},"2026-05-29",{"date":465,"type":40},"2025-07-14",{"date":467,"type":21},"2027-12-31",{"name":469,"class":47},"National Cancer Centre, Singapore",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":56,"minAge":478,"maxAge":479,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":482,"conditions":483,"keywords":485,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":493,"leadSponsor":495,"locationsCount":4},"100640194","robo-paws-robot-dog-assisted-walking-100640194","NCT07603180","ROBO-PAWS: Robot-Dog-Assisted Walking","ROBO-PAWS: A Pilot Randomized Controlled Trial of Robot-Dog-Assisted Walking to Improve Sleep Quality, Fatigue, and Quality of Life in Pediatric Oncology Patients","ROBO-PAWS","Inclusion Criteria:\n\n* Aged between 2 and 7 years,\n* Diagnosed with cancer and currently receiving active treatment,\n* Pain level not severe enough to interfere with mobilization (FLACC or Wong-Baker FACES score ≤ 4),\n* Diagnosed within the previous 1 month,\n* Medically stable and approved by the physician to participate in light-intensity walking activities,\n* Expected to remain hospitalized for at least 1 month to allow completion of the study protocol,\n* Not scheduled for hematopoietic stem cell transplantation (HSCT) and not currently undergoing HSCT,\n* Hemoglobin level adequate for participation in walking activities (\\>10 g\u002FdL),\n* No significant impairment in consciousness, balance, or motor functions due to heavy analgesic or sedative medication use.\n\nExclusion Criteria:\n\n* Resting SpO₂ \\\u003C94%, requirement for ≥2 L\u002Fmin oxygen support, or recurrent desaturation episodes within the last 24 hours,\n* Heart rate or respiratory rate significantly elevated or irregular for age,\n* Hemodynamic instability,\n* Visual, hearing, or severe cognitive impairment that would prevent interaction with the robotic dog,\n* Increased mobilization risk due to high-dose corticosteroid treatment or medications associated with neurotoxicity,\n* Motor function limitations that would interfere with safe walking,\n* Concurrent severe infection or serious treatment-related complications (e.g., grade 3-4 mucositis or severe neutropenia requiring isolation),\n* Children receiving end-of-life care.","2 Years","7 Years",{"count":175,"type":21},[24],"Childhood cancers affect approximately 400,000 children and adolescents worldwide each year. Although advances in treatment have significantly improved survival rates, children undergoing cancer treatment continue to experience a wide range of treatment-related symptoms and complications. Among these, fatigue and sleep disturbances are particularly common and may persist throughout treatment and survivorship, negatively affecting psychological well-being, cognitive functioning, and overall quality of life. Reduced physical activity during treatment is strongly associated with worsening fatigue, impaired sleep, and decreased quality of life in pediatric oncology patients. However, treatment side effects, prolonged hospitalization, infection risk, and lack of motivating play-based activities often limit children's participation in physical activity during treatment. Recent evidence suggests that physical activity interventions may help reduce fatigue and improve well-being in children with cancer, yet engaging and age-appropriate non-pharmacological interventions remain limited, especially for younger children.\n\nThis pilot randomized controlled trial aims to evaluate the feasibility and potential effects of a robot-dog-assisted walking intervention on sleep quality, fatigue, and quality of life among children aged 2-7 years undergoing cancer treatment.",[282,33,484],"Quality of Life",[486,71,487,488],"sleep quality","children","cancer","2026-05-19",{"date":491,"type":40},"2026-05-22",{"date":106,"type":21},{"date":494,"type":21},"2027-06-01",{"name":496,"class":47},"Koç University",{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":56,"minAge":239,"maxAge":505,"enrollmentInfo":506,"targetDuration":4,"studyType":22,"phases":508,"briefSummary":509,"conditions":510,"keywords":512,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":528,"leadSponsor":529,"locationsCount":48},"100637914","reflexology-versus-progressive-muscle-relaxation-for-fatigue-in-hemodialysis-patients-100637914","NCT07575607","Reflexology Versus Progressive Muscle Relaxation for Fatigue in Hemodialysis Patients","Comparative Efficacy of Reflexology and Progressive Muscle Relaxation in Mitigating Fatigue Among Hemodialysis Patients","PMR-HD","Inclusion Criteria:\n\n* Adult patients of both genders aged from 50 to 70 years old.\n* Patients are experiencing moderate to severe fatigue (as measured by a standardized fatigue scale).\n* Medically stable as determined by the attending nephrologist.\n* Able to understand and follow instructions for relaxation techniques\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment or psychiatric disorders that interfere with participation.\n* Patients with foot ulcers, wounds, or any contraindications for foot reflexology.\n* Currently practicing any relaxation or complementary therapies regularly.\n* Patients with unstable medical conditions or undergoing treatment changes during the study period.\n* History of recent surgery.","70 Years",{"count":507,"type":21},60,[24],"The goal of this clinical trial is to compare the effects of reflexology and progressive muscle relaxation in reducing fatigue among hemodialysis patients and to determine which intervention provides greater relief from fatigue.\n\nThe main question it aims to answer is:\n\nIs there any difference in effectiveness between reflexology and progressive muscle relaxation techniques in reducing fatigue levels among patients undergoing hemodialysis?\n\nParticipants will be randomly assigned to one of three groups:\n\nGroup 1: 20 participants will receive reflexology therapy 3 times per week for 12 weeks.\n\nGroup 2: 20 participants will receive progressive muscle relaxation 3 times per week for 12 weeks.\n\nGroup 3: 20 participants will be a control group.\n\nFatigue and sleep quality will be measured before and after the intervention using:\n\nFatigue Severity Scale (FSS) Pittsburgh Sleep Quality Index (PSQI) Epworth Sleepiness Scale (ESS)\n\nThis study aims to offer a safe, low-cost, non-pharmacological method that can help hemodialysis patients reduce fatigue and improve sleep quality.",[511,33],"End Stage Renal Failure, Hemodialysis",[513,514,33,515,516,517,518,519,520,521,522,523],"Reflexology","Relaxation","Sleep quality","Non-pharmacological interventions","Hemodialysis","End-stage renal failure","Progressive muscle relaxation","Fatigue Severity Scale","Pittsburgh Sleep Quality Index","Epworth Sleepiness Scale","Chronic kidney disease","2026-05-08",{"date":526,"type":40},"2026-05-12",{"date":106,"type":21},{"date":108,"type":21},{"name":530,"class":47},"Cairo University",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":56,"minAge":301,"maxAge":539,"enrollmentInfo":540,"targetDuration":4,"studyType":22,"phases":542,"briefSummary":543,"conditions":544,"keywords":551,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":202},"100438049","phase-2-sodium-bicarbonate-and-mitochondrial-energetics-in-persons-with-ckd-100438049","NCT04984226","Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD","Randomized Cross-over Trial of Sodium Bicarbonate on Muscle Mitochondrial Energetics and Physical Endurance in Chronic Kidney Disease and Metabolic Acidosis","Senergy-CKD","Inclusion Criteria:\n\n* Moderate-severe CKD determined by eGFR \\\u003C50ml\u002Fmin per 1.73m2 by CKD EPI equation on at least 2 consecutive occasions.\n* Metabolic acidosis defined as bicarbonate level\\\u003C24 on two consecutive occasions. Bicarbonate level of 24 or less allowed if eGFR\\\u003C=45ml\u002Fmin per 1.73m2\n* Age 21 to 85 years old\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* Poorly controlled diabetes (HgbA1c\\>10%)\n* History of persistent hyperkalemia (K\\>5.4)\n* History of persistent hypokalemia (K\\\u003C3.3)\n* Uncontrolled blood pressure (\\>170\u002F100)\n* Chronic treatment with renal replacement therapy\n* History of aortic dissection or severe valvular heart disease\n* Exercise induced angina\n* Uncontrolled cardiac dysrhythmia\n* Oxygen dependent chronic obstructive pulmonary disease (COPD)\n* Symptomatic claudication\n* End stage liver disease\n* Mobility disability defined as inability to walk without human assistance\n* Dementia or psychosis\n* Patients who cannot consent\n* Active use of intraveneous drugs\n* Non-english speaking\n* History of transplant\n* Implants that prohibit MRI measurements or trauma involving metal fragments\n* Pacemaker\n* Expectation to start dialysis during the course of study.\n* Women who are breastfeeding, pregnant, or are wanting to become pregnant\n* Any condition which in the judgement of the clinical investigator places the participant at risk from participation in the study.\n\nExclusion criteria for optional muscle biopsy\n\n* Drugs- anticoagulants or antiplatelets:\n\n  * Anticoagulants, any 1 (coumadin, rivaroxaban, apixaban, dabigatran, edoxaban)\n  * Antiplatelets, any 2 (aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticragrelor, ticlopidine, vorapaxar)\n* Platelet count \\\u003C100,000\n* International normalized ratio (INR)\\>1.4","85 Years",{"count":541,"type":21},80,[382],"Skeletal muscle metabolic health is critical for mobility and an underrecognized target of metabolic acidosis in chronic kidney disease. Impaired muscle mitochondrial metabolism underlies poor physical endurance increasing the risk of mobility disability. The proposed project will use precise in vivo tools to study the pathophysiology of poor physical endurance in a clinical trial treating metabolic acidosis among persons living with chronic kidney disease.",[545,546,33,547,548,549,550],"Chronic Kidney Diseases","Metabolic Acidosis","Physical Endurance","Insulin Resistance","Mitochondrial Energetics","Diabetes",[552,523,553],"Metabolic acidosis","Insulin resistance","2026-05-04",{"date":556,"type":40},"2026-05-06",{"date":558,"type":40},"2023-09-08",{"date":560,"type":21},"2026-12-31",{"name":562,"class":47},"University of California, Davis",{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":90,"sex":18,"minAge":570,"maxAge":571,"enrollmentInfo":572,"targetDuration":4,"studyType":22,"phases":573,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":48},"100636968","radicle-womens-healthtm-a-study-assessing-the-impact-of-health-and-wellness-products-on-fatigue-and-related-health-outcomes-among-women-experiencing-menopausal-symptoms-100636968","NCT07572578","Radicle Women's HealthTM: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes Among Women Experiencing Menopausal Symptoms","Radicle Women's HealthTM: A Randomized, Double-Blind, Placebo- Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes Among Women Experiencing Menopausal Symptoms","3.1 Inclusion\n\nParticipants must meet all the following criteria:\n\n* Adults, 35-60 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n\n  * Assigned sex at birth is female\n* Experience at least two menopausal symptoms\n* Resides in the United States\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study\n\n3.2 Exclusion\n\nIndividuals who report any of the following during screening may be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English at a 7th grade level\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n\n  * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.\n\n  * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products\n* Reports current use of the primary ingredient(s) and\u002For similar product(s) to the active study product(s) that may limit the effects of the study products and\u002For pose a safety risk\n* Lack of reliable daily access to the internet\n* Reports surgical menopause\u002Fbilateral oophorectomy\n* Reports taking HRT or prescription menopausal products","35 Years","60 Years",{"count":304,"type":21},[24],"Radicle Women's HealthTM: A randomized, double-blind, placebo- controlled direct-to-consumer study assessing the impact of health and wellness products on fatigue and related health outcomes among women experiencing menopausal symptoms.",[33],"2026-05-01",{"date":578,"type":40},"2026-05-07",{"date":580,"type":21},"2026-05-11",{"date":582,"type":21},"2027-05-11",{"name":317,"class":81},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":590,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":145,"enrollmentInfo":592,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":594,"conditions":595,"keywords":597,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":48},"100466749","immunoglobulin-deficiency-a-treatable-cause-of-fatigue-in-patients-with-multiple-sclerosis-ms-100466749","NCT05357781","Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?","Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? - A Prospective Observational Fatigue Trial","FatIgG","Inclusion Criteria:\n\n* Diagnosis of Multiple Sclerosis following McDonald 2017-Criteria\n* Age 18-65 years\n* Stable MS disease at inclusion (definition: no clinical relapse, no MRI activity, stable disability within the last 12 months)\n* Unchanged immunotherapy within the last 12 months\n* Expanded Disability Status Scale (EDSS) level \\\u003C4 points indicating fully ambulatory patients.\n* Capability of written informed consent\n\nExclusion Criteria:\n\n* Severe depression (definition: Beck Depression Index-II (BDI-II) ≥29 points) or other established psychiatric diagnosis\n* Immunodeficiency other than hypogammaglobulinemia\n* Immunglobulin replacement therapy or indication for immunoglobulin replacement therapy\n* Severe Sleepiness (definition: Epworth-Sleepiness-Scale (ESS) \\>16 points)\n* Fatigue aggravating factors such: liver\u002Frenal\u002Fthyroid dysfunction, substance abuse, medication (tranquilizers \u002Fantiepileptics\u002Fpsychopharmaceuticals), chronic infectious disease (like hepatitis\u002FHIV).\n* Other neurodegenerative\u002Fautoimmune disease.\n* Patients not able to give written consent\n* Vulnerable patients such as children, pregnant women and prisoners",{"count":593,"type":21},106,"The investigators hypothesize that hypogammaglobulinemia (defined as IgG serum concentration \\\u003C7.0g\u002FL) is a treatable cause of fatigue in people with MS:\n\nThe primary objective is to prove the link between hypogammaglobulinemia and fatigue in patients with multiple sclerosis.\n\nThe secondary objective is to show that fatigue is mediated via frequent infections in people with MS and hypogammaglobulinemia.",[596,179,33],"Hypogammaglobulinemia",[33,596],"2026-04-30",{"date":576,"type":40},{"date":601,"type":40},"2022-07-01",{"date":603,"type":21},"2026-12-30",{"name":605,"class":47},"Insel Gruppe AG, University Hospital Bern",{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":614,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":48},"100522676","phase-2-combination-therapy-for-cancer-related-fatigue-in-patients-with-metastatic-cancers-100522676","NCT06085716","Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers","Inclusion Criteria:\n\n1. Be advanced cancer patients or s or have a history of advanced cancer, having fatigue with severity of ≥ 4\u002F10, on a 0-10 scale (Edmonton Symptom Assessment Scale), and presence of fatigue for at least 2 weeks.\n2. Have no clinical evidence of cognitive failure as evidenced by treating clinician assessment at screening (Memorial Delirium Assessment Scale of less than 13\u002F30).\n3. Be aged 18 years or older.\n4. Be willing to complete in-person or with research staff, and able to complete Psychoeducational intervention either in person or virtually within Texas.\n5. Have a hemoglobin level of ≥10 g\u002FdL within 2 weeks of enrollment.\n6. Be able to understand the description of the study and sign a written informed consent.\n7. Have a ECOG performance status score of 0 to 2; and\n8. Be seen at an outpatient clinic at MD Anderson Cancer Center's (MDA) main campus or its Houston Area Locations (HALs)\n9. Able to read, write and speak English\n\nExclusion Criteria:\n\n1. Have a major contraindication to placebo (e.g., allergy or hypersensitivity to study medications or their constituents), or conditions making adherence difficult as determined by the attending physician.\n2. Be unable to complete the baseline assessment forms or to understand the recommendations for participation in the study.\n3. Be pregnant (as documented in chart) or become pregnant while on study.",{"count":613,"type":21},240,[382,60],"To find out if combining psychoeducational interventions (such as education, counseling, and self-managed therapies) with an open-label placebo can help to improve your quality of life better than either the psychoeducational interventions or the placebo alone.",[617,33],"Metastatic Cancers","2026-04-29",{"date":620,"type":40},"2026-05-05",{"date":622,"type":40},"2024-02-16",{"date":624,"type":21},"2029-08-31",{"name":445,"class":47},{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":630,"acronym":4,"eligibilityCriteria":631,"healthyVolunteers":90,"sex":56,"minAge":145,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":633,"conditions":634,"keywords":637,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":48},"100636372","association-between-sarcopenia-fatigue-and-orthostatic-intolerance-in-geriatric-patients-a-case-control-study-100636372","NCT07564830","Association Between Sarcopenia, Fatigue and Orthostatic Intolerance in Geriatric Patients: A Case Control Study","Inclusion Criteria:\n\n* Patients (males or females) aged 65 or above years old.\n* Participants who are willing to participate in the study.\n\nExclusion Criteria:\n\n* Patients who are not willing to participate in the study.\n* patients with end organ damage (CHF NYHA III\u002FIV), end-stage renal disease, Liver cell failure, respiratory failure.\n* Patients with arrhythmia or using pacemakers\n* patients diagnosed with parkinsonism, Diabetes mellitus, or peripheral neuropathy.\n* Active infections or inflammatory conditions (e.g., sepsis, rheumatoid flare-up)\n* Patient with acute stroke, Critically ill patients, Terminal illness, Bedridden or completely immobile patients,\n* Medications Influencing Fatigue\u002FOI: High-dose opioids, sedatives, or drugs causing significant orthostatic hypotension (e.g., alpha-blockers, diuretics without stable control)",{"count":405,"type":21},"This study aims to explore the relationship between sarcopenia, fatigue, and orthostatic intolerance in older adults. It will be conducted among geriatric patients attending Ain Shams University Hospitals.\n\nParticipants aged 65 years and older will be divided into two groups: those with sarcopenia, diagnosed according to the European Working Group on Sarcopenia in Older People 2, and age- and sex-matched controls without sarcopenia. The study will compare levels of fatigue and the presence of orthostatic intolerance between the two groups.\n\nThe findings are expected to improve understanding of how sarcopenia is associated with fatigue and orthostatic symptoms in the elderly population, which may help guide better clinical assessment and management.",[635,33,636],"Sarcopenia","Orthostatic Intolerance",[638,639,640],"geriatric","sarcopenia","orthostatic intolerance","2026-04-27",{"date":554,"type":40},{"date":644,"type":21},"2026-05",{"date":646,"type":21},"2027-04",{"name":648,"class":47},"Ain Shams University",{"id":650,"slug":651,"hasResults":12,"nctId":652,"briefTitle":653,"officialTitle":654,"acronym":4,"eligibilityCriteria":655,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":145,"enrollmentInfo":656,"targetDuration":4,"studyType":22,"phases":658,"briefSummary":660,"conditions":661,"keywords":663,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":669,"completionDateStruct":670,"leadSponsor":672,"locationsCount":48},"100636160","phase-1-transcranial-magnetic-stimulation-for-depression-in-multiple-sclerosis-100636160","NCT07562074","Transcranial Magnetic Stimulation for Depression in Multiple Sclerosis","A Pilot Study: Dorsolateral Prefrontal Cortex Transcranial Magnetic Stimulation Target Engagement and Safety in Primary Progressive and Relapsing-remitting Multiple Sclerosis","Inclusion Criteria:\n\n1. 18-65 years of age, inclusive.\n2. Males, females, and non-binary.\n3. Clinical diagnosis of relapsing-remitting or primary-progressive multiple sclerosis according to the revised McDonald criteria and as determined by the study neurologist and medical records.\n4. Expanded Disability Status Scale score \\\u003C7.\n5. Fatigue Severity Scale ≥ 4.\n6. Moderate to severe major depressive disorder as defined by a Hamilton Depression Rating Scale-17 item score ≥18.\n7. Did not benefit adequately from ≥ 1 antidepressant or course of psychotherapy.\n8. Stable immunotherapy for at least 3 months and medications for at least 4 weeks.\n9. Have no contraindications to TMS or magnetic resonance imaging.\n10. Ability to provide written consent obtained from study subject or subject's legal representative and ability for study subject to comply with the requirements of the study.\n11. Are able to adhere to the treatment schedule\n12. Pass the TMS adult safety screening (TASS) questionnaire\n\nExclusion Criteria:\n\n1. Presence of any disease, medical condition, or physical condition that, in the opinion of the study investigator, study psychiatrist, or study neurologist, may compromise interfere, limit, affect, or reduce the study subject's ability to complete the study.\n2. Presence of any disease, medical condition, or physical condition that, in the opinion of the study investigator, study psychiatrist, or study neurologist, may adversely impact the safety of the study subject or the integrity of the data.\n3. History of seizures.\n4. Any cranial metal implants (excluding ≤ 1mm thick epicranial titanium skull plates and dental fillings) or medical devices (i.e. cardiac pacemaker, deep brain stimulator, medication infusion pump, cochlear implant).\n5. Previous surgeries opening the skull leaving skull defects capable of allowing the insertion of a cylinder with a radius ≥ 5mm.\n6. Any diagnosis of a psychiatric diagnosis determined to be primary.\n7. Are at a significant risk of harm to themselves or others.\n8. Have a substance or alcohol use disorder within the last three months.\n9. If participating in psychotherapy, must have been in stable treatment for at least three months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study.\n10. Are currently pregnant, breast feeding, or plan to become pregnant over the duration of the study.\n11. Active suicidal ideation as defined by a score of 4 ≥ on item 10 of MADRS\n12. Have failed a course of ECT in the current episode. Previous ECT treatment outside of the current episode does not influence inclusion.\n13. Have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of epilepsy, cerebral aneurysm, Parkinson's disease, Huntington's chorea, significant head trauma with loss of consciousness for greater than or equal to 5 minutes\n14. Have concomitant major unstable medical illness",{"count":657,"type":21},20,[659],"PHASE1","Canada has one of the highest rates of multiple sclerosis (MS). MS patients experience disabling motor, visual, and sensory symptoms, and a high risk of comorbid major depressive disorder (MDD) and severe fatigue. The lifetime prevalence of MDD in MS patients is about 50%, and nearly 90% experience severe fatigue, both of which are not responsive to typical treatments. Repetitive transcranial magnetic stimulation (rTMS) is a first line, Health Canada approved non-invasive neurostimulation treatment for MDD. rTMS induces electrical activity in the cortex using magnetic fields generated outside of the head to drive neuronal firing in the target site. However, MS is typically an exclusion criterion due to safety concerns.\n\nThe goal of this clinical trial is to learn if repeated transcranial magnetic stimulation (rTMS) can be used to treat depression symptoms in adults with multiple sclerosis (MS). rTMS is a non-invasive form of brain stimulation that uses magnetic pulses to stimulate specific parts of the brain.\n\nThe main questions it aims to answer are:\n\nIs rTMS safe, tolerable, and feasible to deliver as a treatment for depression and fatigue symptoms in individuals with MS? Does rTMS show preliminary effectiveness in improving depression and fatigue symptoms in this population?\n\nResearchers will determine whether rTMS treatment improves mood, fatigue, and cognition across time points (baseline, after treatment, and 4-week follow-up).\n\nParticipants will: Complete screening, questionnaires, clinical assessments, cognitive tests, a brain MRI to help tailor the TMS treatment, and receive daily TMS sessions for 5 consecutive days, including: Pre-TMS brain mapping, five rTMS treatments (3 minutes) per day, separated by one hour. A safety and tolerability questionnaire will be administered daily. Complete post-treatment assessments (questionnaires, cognitive tests, psychiatric evaluation). Complete a 4-week follow-up visit, in person or virtually. Wear a fitness tracking watch during the study so researchers can collect activity data remotely.\n\nAbout 20 people will take part in this study through the University of Calgary.",[179,662,33],"Depression - Major Depressive Disorder",[179,664,665,361,666],"TMS","rTMS","Brain Stimulation","2026-04-24",{"date":576,"type":40},{"date":365,"type":21},{"date":671,"type":21},"2027-12-30",{"name":673,"class":47},"University of Calgary",{"id":675,"slug":676,"hasResults":12,"nctId":677,"briefTitle":678,"officialTitle":679,"acronym":4,"eligibilityCriteria":680,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":4,"enrollmentInfo":681,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":682,"conditions":683,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":685,"lastUpdatePostDateStruct":686,"startDateStruct":687,"completionDateStruct":689,"leadSponsor":691,"locationsCount":48},"100634800","explanatory-factors-and-predictors-of-fatigue-in-patients-with-sjgrens-disease-a-3-month-longitudinal-study-100634800","NCT07544394","Explanatory Factors and Predictors of Fatigue in Patients With Sjögren's Disease: A 3-month Longitudinal Study","Explanatory Factors and Predictors of Fatigue in Patients With Sjögren's Disease: A 3-Month Longitudinal Study","Inclusion Criteria:\n\n* Diagnosis of Sjögren's syndrome\n* Age ≥ 18 years\n* Willingness to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Presence of severe somatic or psychiatric disorders\n* Presence of malignancy\n* Pregnancy\n* Refusal to participate or inability to provide written informed consent",{"count":267,"type":21},"This prospective longitudinal study will be conducted in patients diagnosed with Sjögren's disease who are followed at the rheumatology outpatient clinic of Kahramanmaras Sutcu Imam University Medical Faculty Hospital. Demographic and clinical data will be collected from routine clinical assessments and medical records, including laboratory results obtained during standard care.\n\nParticipants will undergo evaluation of pressure pain threshold using a digital algometer and complete validated questionnaires assessing fatigue, disease activity, patient-reported symptoms, anxiety and depression, pain catastrophizing, sleep quality, and physical activity level.\n\nAll assessments will be performed at baseline and repeated at follow-up visits approximately 3 months later.",[684,33],"Sjogren's Disease","2026-04-22",{"date":641,"type":40},{"date":688,"type":40},"2026-04-20",{"date":690,"type":21},"2028-04-20",{"name":692,"class":47},"Kahramanmaras Sutcu Imam University"]